Long-term platinum retention after treatment with cisplatin and oxaliplatin.
about
Chemotherapy-induced peripheral neurotoxicity: a critical analysis[EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Testicular cancer survivorship: research strategies and recommendations.The interaction of platinum-based drugs with native biologically relevant proteins.Oxaliplatin: a review in the era of molecularly targeted therapyPalladium(II) and platinum(II) bind strongly to an engineered blue copper protein.Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluationSolid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.Cardiovascular disease in cancer survivors.Long-term hearing loss after chemoradiation in patients with head and neck cancer.Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues.Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female miceRate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.Adolescents and young adults with a "rare" cancer: getting past semantics to optimal care for patients with germ cell tumorsGene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro.COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.Early development of the metabolic syndrome after chemotherapy for testicular cancer.Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.Long-Term and Latent Side Effects of Specific Cancer Types.Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.Prophylaxis of hereditary breast cancer.Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.Effects of Oxaliplatin Treatment on the Myenteric Plexus Innervation and Glia in the Murine Distal Colon
P2860
Q27010318-F1FCB8FE-B68D-4545-8C5E-8F21C982620CQ33824948-E0341733-3C2E-4287-A729-3B8B1E6D7C1FQ34039684-B371D33E-300D-4D6C-8278-B510FD06F672Q34439746-FA4765F8-F063-46C4-A2C1-D90C358F8748Q34541434-0D191215-CF0F-4D11-A758-2EC77E4BAAEEQ35553261-F48350B4-A8F0-4FF8-8F79-F96227E79050Q35721076-DCF5A357-1009-4C3E-BC6A-14433F3FD147Q36207925-C860CADC-0A39-450A-B3C2-08A47FEC8A29Q36753313-FFFDE46B-BF54-4324-980C-013EC6D5EA31Q37227682-FF89E628-2E48-4F9B-B462-E8EF3EDD5452Q38287054-408ADA97-17D0-49BD-AEC2-F34A371D3DECQ39103481-370AB26E-5B1E-4FCB-B52E-742032369201Q39169987-D315FAEF-6594-4816-8FB2-CAF3B05665C4Q41671334-662520DB-49DA-4142-861E-6C7B6512758DQ42365244-DDCD1D1F-6584-49F9-98F3-8230C978612AQ42650614-C6B126DB-E7F7-4695-86B2-9A123F81BCE6Q42716527-F2D7281F-B82F-4A78-9198-2B178B743C33Q42734042-288B42C6-8256-472A-8E5A-CA0EB871191EQ43529077-9F61E514-FCDB-40DD-B24B-960DE0C559B5Q46263274-61FB9F32-845F-4D22-9616-2114E3888F1FQ46493654-C14EF0E4-2A97-4081-80B5-E5D79FD79927Q47563582-BF594D9C-3E2F-4609-B155-3EEC931CA4DEQ47602301-53F258A2-C1BE-40C3-BAC9-F0150BF5785AQ47681122-FD3D6033-454A-46A7-8458-9521B55E9866Q49375528-EB0CD354-34E2-4669-AF1E-F5AE229B2196Q50111382-3A8480CD-4E8F-4C72-88FF-5ACEBB735824Q53058208-0D76FC10-EAC6-4061-9801-3D39B4D0D8E1
P2860
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@ast
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@en
type
label
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@ast
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@en
prefLabel
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@ast
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@en
P2093
P2860
P356
P1476
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
@en
P2093
Alwin D R Huitema
Elke E M Brouwers
Jan H M Schellens
Jos H Beijnen
P2860
P2888
P356
10.1186/1472-6904-8-7
P577
2008-09-17T00:00:00Z
P5875
P6179
1031162593